Stock BDSX BIODESIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Biodesix, Inc.

Equities

BDSX

US09075X1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
1.39 USD +4.51% Intraday chart for Biodesix, Inc. +3.73% -24.46%
May. 21 Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting CI
May. 13 TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Biodesix, Inc. Reaffirms Revenue Guidance for the Full Year 2024
Top Midday Decliners
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center
Biodesix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Biodesix, Inc. Provides Revenue Guidance for the Year 2024
Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method
Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Biodesix, Inc. Provides Revenue Guidance for the Year 2023
Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023
Biodesix Says Study Evaluating Nodify XL2 Test for Benign Lung Nodules Achieves Primary Endpoint; Shares Rise Pre-Bell
Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BDSX Stock
  4. News Biodesix, Inc.
  5. Other languages